Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Precigen, Inc. Common Stock

PGEN

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Last trade $4.23
Day change -$0.07 (-1.63%)
Day range $4.21 – $4.37
Volume 2,319,526
Market cap $1.54B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.54B
Price / earnings
63.17×
Price / book
18.4×
Price / sales
9.82×
EV / sales
10.33×
EV / EBITDA
42.57×

Profitability

Earnings per share
$0.07
Return on assets
11.51%
Return on equity
29.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.12×
Current ratio
5.58×
Quick ratio
4.83×
Cash ratio
0.49×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$74.32M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PGEN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$74.15M$54.98M$23.25M$4.57M$2.92M$856K$1.34M$1.19M
Cost of revenue$6.51M$2.81M$2.56M$1.6M$1.04M$1.09M$1.1M$1.17M
Gross profit$67.64M$52.17M$20.69M$2.97M$1.89M-$236K$241K$21K
Selling, general and administrative$22.36M$22.25M$21.05M$17.65M$23.99M$16.13M$12.36M$11M
Research and development$6.63M$7.28M$5.64M$6.99M$12.38M$11.49M$10.48M$11.76M
Total operating expenses$28.99M$29.53M$26.69M$24.64M$36.37M$31.53M$22.84M$28.54M
Operating income$38.65M$22.64M-$5.99M-$21.67M-$34.48M-$31.76M-$22.6M-$28.52M
Interest expense-$3M-$2.95M-$2.91M-$2.96M-$902K$0-$1K$0
Income before taxes$35.97M$20.07M-$7.93M-$23.5M-$146.34M-$26.64M-$54.15M-$19.81M
Income taxes$200K$0$0$0$0$3K$0-$87K
Net income$35.77M$20.07M-$7.93M-$23.5M-$146.34M-$26.64M-$54.15M-$19.73M
Net income attributable to common shareholders$35.77M$20.07M-$7.93M-$23.5M-$325.34M-$26.64M-$54.15M-$19.73M
EBITDA$39.76M$23.74M-$4.9M-$20.53M-$33.68M-$27.23M-$21.97M-$22.08M
Basic earnings per share$0.10$0.06-$0.02-$0.07-$1.06-$0.09-$0.18-$0.07
Diluted earnings per share$0.08$0.05-$0.02-$0.07-$1.06-$0.09-$0.18-$0.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

What Makes Precigen (PGEN) a New Buy Stock

Precigen, Inc. (PGEN) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $0.27 per share, but analysts have raised estimates by 6.7% over the past three months. The upgrade positions PGEN in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.

Zacks Investment Research

PGEN Q3 Earnings Call Highlights Launch Momentum and Competition

Precigen (PGEN) reported Q3 2026 revenues of $74.15M, slightly missing consensus estimates, with PAPZIMEOS generating $72.9M in net revenue, up 37% sequentially. The company treated over 500 patients and achieved positive operating cash flow of $11.9M. Management emphasized the therapy's 51% complete response rate and competitive advantages while preparing for upcoming competition from Inovio. The company is pursuing redosing trials, pediatric development, and international expansion opportunities.

Zacks Investment Research

Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates

Precigen (PGEN) reported Q3 2026 earnings of $0.08 per share, missing the consensus estimate of $0.09, though revenues of $74.15 million exceeded expectations. The stock has outperformed the S&P 500 by 15% year-to-date and holds a Zacks Rank #3 (Hold) rating. Monte Rosa Therapeutics (GLUE) is expected to report a quarterly loss of $0.10 per share with revenues projected at $45.33 million.

Zacks Investment Research

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Precigen is set to report Q3 2026 earnings on Nov. 4 with expected revenues of $75.4 million and EPS of 9 cents. The company's sole marketed drug Papzimeos has shown strong sales momentum, but faces new competitive pressure following FDA approval of Inovio's Voceryq for the same indication (RRP). Precigen's stock fell ~20% following the competitive approval. The company's earnings surprise model does not predict a beat this quarter.

Zacks Investment Research

Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus

Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.